La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Apellis Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Apellis Pharmaceuticals' Il CEO è Cedric Francois, nominato in Sep2009, e ha un mandato di 14.92 anni. la retribuzione annua totale è $ 10.37M, composta da 7.1% di stipendio e 92.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.51% delle azioni della società, per un valore di $ 71.44M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 9.1 anni.

Informazioni chiave

Cedric Francois

Amministratore delegato

US$10.4m

Compenso totale

Percentuale dello stipendio del CEO	7.1%
Mandato del CEO	14.9yrs
Proprietà del CEO	1.5%
Durata media del management	5.5yrs
Durata media del Consiglio di amministrazione	9.1yrs

Aggiornamenti recenti sulla gestione

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Recent updates

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09

Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise

Sep 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Cedric Francois rispetto agli utili di Apellis Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

Compensazione vs Mercato: La retribuzione totale di Cedric ($USD 10.37M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.42M ).

Compensazione vs guadagni: La retribuzione di Cedric è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Cedric Francois (52 yo)

14.9yrs

Mandato

US$10,373,049

Compensazione

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Cedric Francois	Co-Founder	14.9yrs	US$10.37m	1.51% $ 73.1m
Alec Machiels	Co-Founder & Director	15.6yrs	US$495.96k	0.64% $ 30.9m
Timothy Sullivan	CFO & Treasurer	6.8yrs	US$3.74m	0.084% $ 4.1m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% $ 1.1m
David Watson	General Counsel	10.6yrs	US$4.89m	0.094% $ 4.6m
Caroline Baumal	Chief Medical Officer	1.6yrs	US$4.43m	0.0052% $ 249.9k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	14.9yrs	US$3.08m	0.91% $ 44.4m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3yrs	Nessun dato	0.0085% $ 411.5k
Meredith Kaya	Senior Vice President	no data	Nessun dato	Nessun dato
Karen Lewis	Chief People Officer	4.3yrs	Nessun dato	0.00073% $ 35.4k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Victoria Brown	Senior Vice President	5.5yrs	Nessun dato	0.0031% $ 150.0k

5.5yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di APLS è esperto e expertise (durata media dell'incarico 5.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Cedric Francois	Co-Founder	14.9yrs	US$10.37m	1.51% $ 73.1m
Alec Machiels	Co-Founder & Director	14.9yrs	US$495.96k	0.64% $ 30.9m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Lokchung L. Chan	Independent Chairman of the Board	11.1yrs	US$504.08k	0.00056% $ 27.2k
Stephanie O'Brien	Independent Director	11.1yrs	US$488.46k	0.00056% $ 27.2k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Robert Brodsky	Member of PNH Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Paul Fonteyne	Independent Director	4.3yrs	US$489.08k	0.0047% $ 226.1k
A. Dunlop	Independent Director	14.4yrs	US$480.96k	0.11% $ 5.2m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	Nessun dato	Nessun dato
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato

9.1yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di APLS sono considerati esperti (durata media dell'incarico 9.1 anni).

Apellis Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director notifies of intention to sell stock

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100

Chief Commercial Officer notifies of intention to sell stock

Insufficient new directors

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Chief Commercial Officer notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Co-Founder exercised options to buy US$6.5m worth of stock.

Co-Founder & Director exercised options and sold US$62k worth of stock